Apolipoprotein E (ApoE) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Apolipoprotein E (ApoE) – Pipeline Review, H2 2016’, provides in depth analysis on Apolipoprotein E (ApoE) targeted pipeline therapeutics.

The report provides comprehensive information on the Apolipoprotein E (ApoE) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Apolipoprotein E (ApoE) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Apolipoprotein E (ApoE)

The report reviews Apolipoprotein E (ApoE) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Apolipoprotein E (ApoE) targeted therapeutics and enlists all their major and minor projects

The report assesses Apolipoprotein E (ApoE) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Apolipoprotein E (ApoE) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Apolipoprotein E (ApoE)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Apolipoprotein E (ApoE) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

LipimetiX Development Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Apolipoprotein E (APOE) Overview 6

Therapeutics Development 7

Apolipoprotein E (APOE) - Products under Development by Stage of Development 7

Apolipoprotein E (APOE) - Products under Development by Therapy Area 8

Apolipoprotein E (APOE) - Products under Development by Indication 9

Apolipoprotein E (APOE) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Apolipoprotein E (APOE) - Products under Development by Companies 12

Apolipoprotein E (APOE) - Products under Development by Universities/Institutes 14

Apolipoprotein E (APOE) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 20

Apolipoprotein E (APOE) - Companies Involved in Therapeutics Development 22

LipimetiX Development Inc 22

Apolipoprotein E (APOE) - Drug Profiles 23

AEM-28 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

AEM-2802 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

AEM-2814 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Monoclonal Antibodies to Target ApoE for Alzheimer's Disease - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Recombinant ApoE4 for Dyslipidemia - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Small Molecules to Activate ApoE for Alzheimer's Disease - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Apolipoprotein E (APOE) - Featured News & Press Releases 31

Oct 14, 2015: Capstone Therapeutics Announces Allowance of U.S. Patent for Treatment of Diabetes With Apo E Mimetic Peptides 31

Jul 23, 2015: Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides 31

Dec 16, 2014: Capstone Therapeutics Announces Phase 1b/2a Study Results for AEM-28 Showing Safety and Biomarker Efficacy Signals 32

Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals 33

Jun 11, 2014: Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1b/2a Human Clinical Trial in Refractory Hypercholesterolemic Subjects 34

Jun 05, 2014: ApoE Immunotherapy and Prions Advance in Alzheimer’s Research 35

Apr 08, 2014: Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1 Human Clinical Trial in LDL/non-HDL Cholesterol Reduction 35

Nov 19, 2013: Capstone Therapeutics Announces a LipimetiX Development Presentation at the American Heart Association Scientific Sessions: Pre-Clinical Data Demonstrating Significant Post Treatment Benefit of AEM-28 on Established Atherosclerotic Lesions 36

Dec 06, 2012: Capstone Therapeutics's Partner LipimetiX Obtains Orphan Drug Designation For AEM-28 To Treat Homozygous Familial Hypercholesterolemia 37

Appendix 38

Methodology 38

Coverage 38

Secondary Research 38

Primary Research 38

Expert Panel Validation 38

Contact Us 38

Disclaimer 39

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by LipimetiX Development Inc, H2 2016 22

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Mechanism of Actions, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports